Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.98 GBX | -1.19% | +2.89% | -4.95% |
Mar. 26 | Scancell doses first patient in melanoma-focused trials | AN |
Mar. 22 | Seneca Growth Capital announces tepid 2023 results | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.95% | 105M | |
+30.75% | 49.46B | |
+1.16% | 42.58B | |
+49.11% | 42.49B | |
-5.26% | 29.09B | |
+12.78% | 26.61B | |
-23.76% | 18.64B | |
+7.38% | 13.16B | |
+31.42% | 12.55B | |
+23.46% | 12.1B |
- Stock Market
- Equities
- SCLP Stock
- News Scancell Holdings plc
- Scancell’s Skin Cancer Vaccine Trial Advances to Second Stage; Shares Up